Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
So what: Cubist said it will pay $13.50 per share in cash for Trius and a $2.00 per share bonus if Trius meets certain sales targets, with the collective $15.50 offer representing a 32% premium to Trius' closing price on Tuesday. Cubist is buying Trius along with Optimer Pharmaceuticals (UNKNOWN: OPTR.DL ) to strengthen its position in antibiotics, and judging by Cubist's 10% pop today, Mr. Market is pleased with the price it's paying to do it.
Now what: Cubist expects the transaction to close later this year, subject to required regulatory approvals and other customary closing conditions.
"Trius is a tremendous strategic fit with Cubist that supports our Building Blocks of Growth long-range goals while extending our global leadership in the acute care environment," said Cubist CEO Michael Bonney. "Tedizolid is an exciting late-stage antibiotic candidate that we believe has the potential to be an important new tool in the infectious disease community's battle against resistant infections caused by MRSA."
So while Trius is likely all popped out at this point, Cubist's expanded presence in the increasingly attractive antibiotics space is certainly worth looking into.
The best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.